Results 51 to 60 of about 4,142 (167)

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open
Objectives To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase ...
Iain B McInnes, Laura C Coates, Philipp Sewerin, Frédéric Lavie, Mohamed Sharaf, Miriam Zimmermann, Michela Efficace   +6 more
doaj   +1 more source

Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
No evidence of an increased risk of incident cancer or KC was observed with biologic versus non‐biologic systemic therapies or across the biologic classes evaluated. Abstract Background There are concerns that biologic therapies for psoriasis may increase cancer risk. Objectives To compare risks of (i) incident cancer excluding keratinocyte carcinomas (
Oras A. Alabas, Kayleigh J. Mason, Mark Lunt, Sarah Ryan, Nick J. Reynolds, Catherine H. Smith, Christopher B. Bunker, Christopher E. M. Griffiths, Adele C. Green, Richard B. Warren   +9 more
wiley   +1 more source

Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study

International Journal of Dermatology, Volume 65, Issue 12, Page 2524-2531, December 2026.
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel, Sandra Schuh, Julia Welzel, Michael Sticherling, Lukas Sollfrank, Carola Berking, Teodora Pumnea, Valerie Glatzel, Lars French, Felix Lauffer, Martin Valentin Vitus, Tilo Biedermann, Susanne Bauer, Michael Spindler, Mark Berneburg, Dennis Niebel   +15 more
wiley   +1 more source

Protocol for the Therapy Personalisation Using Multiomic Analyses in Inflammatory Bowel Disease (THAMES‐IBD) Study

JCC Plus, Volume 1, Issue 6, November 2026.
ABSTRACT Background Despite an expanding repertoire of advanced therapies for inflammatory bowel disease (IBD), treatment outcomes remain suboptimal, with only 30%–40% of patients achieving sustained remission. Emerging evidence indicates that therapeutic outcomes are shaped by complex interactions between host immune pathways, the gut microbiome and ...
John P. Thomas, Aamir Saifuddin, Sadek Malas, Meztli Matadamas Guzman, Cristina Di Poto, Dimple Dixit, Isabel Laszczak, H. Sophia Chung, Erik L. Allman, Yang Song, James L. Alexander, Bat‐Erdene Jugder, Ailsa Hart, Kyle Bednar, Nick Powell   +14 more
wiley   +1 more source

Establishing Stakeholder Priorities for Development of a Multi‐Arm Multi‐Stage Platform Trial in Crohn's Disease

JCC Plus, Volume 1, Issue 6, November 2026.
An international modified Delphi study identified stakeholder consensus on population, interventions, comparators and outcomes to inform development of a future multi‐arm, multi‐stage adaptive platform trial for Crohn's disease. ABSTRACT Background and Aims The expanding range of advanced therapies for Crohn's disease (CD) has increased complexity in ...
Shellie J. Radford, Nurulamin Noor, Daniel Lightowler, Jonathan Segal, Patricia Kelly, Shahida Din, Klaartje B. Kok, Shaji Sebastian, Peter Irving, Charles Maxwell‐Armstrong, Stuart Taylor, Rachel Cooney, James Lindsay, Bruce E. Sands, Remo Panaccione, Gordon W. Moran   +15 more
wiley   +1 more source

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

Journal of Dermatological Treatment
Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.Methods ...
Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, Lilian Diaz, Patrick Lefebvre, Steven R. Feldman   +7 more
doaj   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang, Siwen Wu, Yusi Wang, Die Hu, Li Yang   +4 more
wiley   +1 more source

Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

Rheumatology and Therapy
Introduction Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with ...
Jeffrey R. Curtis, Atul Deodhar, Enrique R. Soriano, Emmanouil Rampakakis, May Shawi, Natalie J. Shiff, Chenglong Han, William Tillett, Dafna D. Gladman   +8 more
doaj   +1 more source

Successful bimekizumab retreatment after secondary failure in multi‐biologic‐resistant psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Nicole Kah Mun Yoong, Melinda Withington, Francis Yi Xing Lai, Paul Curnow, Senhong Lee   +4 more
wiley   +1 more source

Effect of Anti‐IL‐23 and Anti‐IL‐17 Therapy on Darier Disease: A Case Series

Australasian Journal of Dermatology, Volume 67, Issue 7, Page 414-419, November 2026.
ABSTRACT Darier disease is a rare ATP2A2‐related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real‐world case series of eight patients, anti‐IL‐17 therapy showed a more consistent early signal of clinical benefit than anti‐IL‐23 therapy, with greater
Maione Vincenzo, Zanghi Silvia, Catapano Cecilia, Bighetti Stefano, Cattaneo Isacco, Venturini Marina, Bettolini Luca   +6 more
wiley   +1 more source